OncoMatch/Clinical Trials/NCT05747625
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Is NCT05747625 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Panitumumab and Zirconium Zr 89 Panitumumab for head and neck squamous cell carcinoma.
Treatment: Panitumumab · Zirconium Zr 89 Panitumumab — The goal of this phase I clinical trial is to evaluate the usefulness of an imaging test (zirconium Zr89 panitumumab \[89Zr panitumumab\]) with positron emission tomography (PET)/computed tomography (CT) for diagnosing the spread of disease from where it first started (primary site) to other places in the body (metastasis) in patients with head and neck squamous cell carcinoma. Traditional PET/CT has a low positive predictive value for diagnosing metastatic disease in head and neck cancer. 89Zr panitumumab is an investigational imaging agent that contains radiolabeled anti-EGFR antibody which is overexpressed in head and neck cancer. The main question this study aims to answer is the sensitivity and specificity of 89Zr panitumumab for the detection of indeterminate metastatic lesions in head and neck cancer. Participants will receive 89Zr panitumumab infusion and undergo 89Zr panitumumab PET/CT 1 to 5 days after infusion. Participants will otherwise receive standard of care evaluation and treatment for their indeterminate lesions. Researchers will compare the 89Zr panitumumab to standard of care imaging modalities (magnetic resonance imaging (MRI), CT, and/or PET/CT).
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage ANY T STAGE
Subjects diagnosed with any T stage, any subsite within the head and neck. Subjects with recurrent disease or a new primary will be allowed
Lab requirements
Blood counts
Hemoglobin >= 9gm/dL; White blood cell count > 3000/mm^3; Platelet count >= 100,000/mm^3
Kidney function
Serum creatinine <= 1.5 times upper reference range; severe renal disease or anuria excluded
Hemoglobin >= 9gm/dL; White blood cell count > 3000/mm^3; Platelet count >= 100,000/mm^3; Serum creatinine <= 1.5 times upper reference range; Severe renal disease or anuria [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Vanderbilt University/Ingram Cancer Center · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify